dolasetron

Dolasetron is a selective serotonin 5-HT3 receptor antagonist used primarily to prevent and treat nausea and vomiting associated with chemotherapy (CINV), radiotherapy, and postoperative states (PONV). It works by blocking the action of serotonin at 5-HT3 receptors on vagal nerve terminals in the periphery and centrally in the chemoreceptor trigger zone. Its active metabolite hydrodolasetron also contributes to its antiemetic effect. Dolasetron has minimal affinity for dopamine receptors. The drug is available as both oral tablets and intravenous injection; it is generally administered shortly before chemotherapy or surgery. Dolasetron was originally developed by Hoechst Marion Roussel (now part of Sanofi) and first marketed in Australia in 1997[2][5]. It has been included on the WHO Model List of Essential Medicines[1]. Caution is required due to potential cardiac effects such as QT prolongation; regulatory agencies have restricted some indications due to this risk[9].

Brand names

AnzemetZamanonAneme立必复

Other names

多拉司琼dolasetron mesylate甲磺酸多拉司琼